Ulcerative colitis
Conditions
Interventions
Experimental group : Experimental group (TEA) : Zusanli acupoint electrical stimulation treatment (Zusanli acupoint location: located in the depression of the tibial tubercle, one finger width away f
control group:Control group (sham-TEA) : sham acupoint electrical stimulation treatment (sham acupoint location: 10 cm below Zusanli acupoint, 3-4 cm on the side of the non-acupoint) for 8 weeks.
Sponsors
Shanghai Changzheng Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1.Willing to sign informed consent; 2.Age 18-75 years old, gender is not limited; 3.Diagnosis of UC at least 3 months (12 weeks) before baseline; 4.Eligible patients had clinical and endoscopic active ulcerative colitis, with a total Mayo score of 4-10, and a Mayo endoscopic subscore of 1 or more, and the overall evaluation of the physician was <=2.
Exclusion criteria
Exclusion criteria: 1.Patients who have previously received surgical treatment for UC or may need surgical treatment during the study period (such as complications such as bleeding, intestinal perforation, toxic megacolon); 2.There is evidence of pathogenic intestinal infections, including Clostridium difficile toxins or other intestinal pathogens (CMV, EBV, fungi, etc.) screening positive; 3.Subjects with short bowel syndrome and ostomy; 4.Have a history of other digestive diseases (such as IBS, diverticulitis), malignant tumors, and immune deficiency; 5.serious heart, lung, cerebrovascular diseases; 6.Subjects who are currently receiving the following treatment and do not receive a stable dose within the specified time period will not be able to participate in the study: 6.1 The oral stable dose of 5-ASA preparation has not reached 4 weeks; Or if discontinued recently, less than 4 weeks. 6.2 Oral glucocorticoids at the equivalent dose of prednisone greater than 20mg/ day, or 100, stool >10 times a day); 16.Any other participant deemed unsuitable by the researcher.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical remission rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Endoscopic improvement;Symptom improvement;Quality of life improvement;Cytokine level;Heart rate variability; | — |
Countries
China
Contacts
Public ContactShi Bin
Changzheng Hospital, Naval Medical University
Outcome results
None listed